Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Phase II Study of Non-myeloablative Chemotherapy Followed by Tumor Infiltrating Lymphocytes and Interleukin-2 in Metastatic Melanoma
2010-021885-31Phase 2Terminated
- Sponsor
- Netherlands Cancer Institute
- Start
- Dec 2010
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of autologous tumor-infiltrating lymphocytes in melanoma (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Progression-free survival. Started Dec 2010; status: terminated.
02
Drugs
autologous tumor-infiltrating lymphocytes
03
Conditions
melanoma
Beyond the preview
Go deeper on 2010-021885-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021885-31.